Merck lifts 2026 profit and sales forecast after third quarter
Merck raised its 2026 adjusted EPS outlook to $2.77–2.82 and its sales range to $66.8–67.3 billion. Shares were up before the open on Thursday.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Merck & Co. (MRK), which operates as MSD in markets beyond the US and Canada, increased its full-year 2026 forecast on Thursday alongside its third-quarter results, according to TradingView, citing RTTNews. Adjusted earnings per share are now expected between $2.77 and $2.82, compared with the earlier range of $2.66 to $2.76.
The sales outlook has also changed: it now sits between $66.8 billion and $67.3 billion, versus a previous range of $66.3 billion to $67.3 billion. The updated figures include a one-time charge of $0.12 per share linked to a global licensing agreement with SciBrunch Therapeutics Co., Ltd.
In pre-market trading on Thursday, Merck shares on the NYSE were quoted at $144.01, up $2.97, or 2.11 percent.
why it matters
A higher forecast from a major drugmaker typically lifts sentiment across the healthcare sector. Because the new numbers carry a one-time licensing expense, investors will need to separate the operating improvement from the accounting effect.
market impact
Merck (MRK): higher 2026 guidance supports the stock, though a one-time licensing charge partly offsets the gain
- Merck shares (MRK) pressure up — raised profit and sales guidance supports investor expectations
tags
instruments
sources
- ROUNDUP: Merck Boosts FY26 Outlook — TradingView, 29 October 2026 at 11:17 UTC
- ROUNDUP: WEC Energy Boosts FY26 EPS Outlook — TradingView, 29 October 2026 at 12:55 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗